Nerinetide
A stroke neuroprotectant whose benefit may depend on alteplase
Nerinetide is a 20-amino-acid peptide designed to protect brain cells during a stroke by interfering with post-synaptic density protein 95. It worked in animal models, but three large human trials missed their primary outcomes. The recurring hint is that it may help patients undergoing thrombectomy who have not been given alteplase.
Used in human trials: 2.6 mg/kg (maximum 270 mg), Single dose, Intravenous (Trial: ESCAPE-NA1) Details ↓
Recommended Dosing
Used in human trials
No manufacturer dose exists for this use: these are amounts given in published trials, not recommendations.
What is it?
Nerinetide was tested in a setting chosen to mirror the animal models in which it worked: patients whose blocked artery is reopened quickly by endovascular thrombectomy, so that the drug can act on ischaemia-reperfusion injury. The ESCAPE-NA1 investigators describe it as an eicosapeptide that interferes with post-synaptic density protein 95 and is effective in preclinical stroke models of ischaemia-reperfusion.
In ESCAPE-NA1, 1,105 patients undergoing thrombectomy were randomised. Good functional outcome at 90 days was 61.4% on nerinetide against 59.2% on placebo, not significant; but the investigators found evidence that the treatment effect was inhibited in patients who had also received alteplase. Imaging sub-studies found less early infarct growth with nerinetide in the no-alteplase group.
ESCAPE-NEXT then tested nerinetide in 850 thrombectomy patients without prior alteplase, and found no benefit (45% against 46% good outcome). FRONTIER gave it in the ambulance within three hours of symptoms to 532 people and also missed its primary outcome, though results in confirmed ischaemic stroke leaned towards nerinetide. Serious adverse events were similar to placebo in all three trials. It is not approved anywhere.
Meta-analyses of the three phase 3 trials, 2,462 patients in all, agree on the reading: no improvement in functional recovery or infarct size, with a borderline mortality reduction (risk ratio 0.86) that does not settle the question. Pooled analysis of thrombectomy patients who had not received thrombolysis, the group the first trial pointed to, found no benefit.
The trials have left a useful dataset. Imaging follow-up showed the brain keeps losing volume for months after thrombectomy, unaffected by nerinetide, and exploratory analyses suggest brain frailty matters more for outcomes in women. Laboratory work continues on versions that survive longer or reach the brain better, so far without success.
Mechanism of Action
Nerinetide (NA-1) is an eicosapeptide that interferes with postsynaptic density protein 95 (PSD-95) and was effective in preclinical stroke models of ischaemia-reperfusion.
PSD-95 uncoupling
It interferes with PSD-95; in rats it lowered neuronal nitric oxide synthase after arterial occlusion.
Blood-brain barrier
In rats it preserved the barrier after arterial occlusion; PSD-95 is also present in brain endothelial cells.
Alteplase interaction
ESCAPE-NA1 suggested alteplase blunted its effect, but a trial without alteplase found no benefit.
Published Research
The trials of nerinetide, from their PubMed abstracts.
ESCAPE-NA1
In 1,105 thrombectomy patients, 61.4% on nerinetide and 59.2% on placebo had a good outcome (mRS 0-2) at 90 days (risk ratio 1.04, p = 0.35); alteplase appeared to inhibit the treatment effect, and serious adverse events were equal.
ESCAPE-NEXT
In 850 thrombectomy patients without prior thrombolysis, 45% on nerinetide and 46% on placebo achieved mRS 0-2 at 90 days (odds ratio 0.97, p = 0.82); serious adverse events were similar.
FRONTIER: given by paramedics
In 532 people treated in the field a median of 64 minutes after onset, favourable outcome was 57% against 58% (adjusted odds ratio 1.05); in the 302 with ischaemic stroke, results leaned towards nerinetide without reaching significance.
Infarct growth without alteplase
In ESCAPE-NA1 patients with perfusion imaging, alteplase modified nerinetide's effect on infarct growth (P = 0.005); among patients not given alteplase, infarct growth over 24 hours was larger with placebo than with nerinetide.
REPERFUSE MRI sub-study
In 67 patients with adequate MRI after thrombectomy, median infarct volume (12.98 vs 10.80 mL) and early infarct growth (5.92 vs 10.80 mL) did not differ significantly between nerinetide and placebo, and alteplase modified nerinetide's effect on growth in white matter and basal ganglia.
Pooled early-window patients
Pooling 690 patients from three trials treated early and without alteplase, 56% on nerinetide against 48% on placebo reached a good outcome at 90 days (adjusted odds ratio 1.48), with no safety concerns. It is a post hoc analysis.
ESCAPE-NEXT at one year
Among 442 participants with a one-year visit, functional independence was 48.0% on nerinetide and 47.9% on placebo; in the early-window subgroup it was 52.6% against 45.5%, a subgroup result.
Brain frailty and sex in ESCAPE-NA1
In 1,102 ESCAPE-NA1 patients, markers of brain frailty such as cortical atrophy were associated with worse 90-day outcomes in women in exploratory analyses, without a formal sex interaction.
Delayed injury after thrombectomy
In 43 REPERFUSE-NA1 patients, the brain lost volume over the following months after thrombectomy, and baseline infarct size and atrophy predicted independence; nerinetide was not associated with less atrophy.
Health economics
A modelling study estimated a higher net monetary benefit for adding nerinetide to thrombectomy in patients who cannot receive alteplase.
Meta-analysis of three trials
Pooling ESCAPE-NA1, ESCAPE-NEXT and FRONTIER (2,462 patients), nerinetide showed a borderline mortality reduction (risk ratio 0.86, p = 0.05) but no difference in functional recovery or infarct volume; adverse events were similar.
A second meta-analysis
Another pooled analysis of the same three trials reached the same reading: a small, borderline mortality signal, possibly larger without alteplase, and no functional benefit.
Thrombectomy without thrombolysis
In 1,394 thrombectomy patients who had not received thrombolysis, pooled across three trials, nerinetide did not improve 90-day outcomes (mRS 0-2 risk ratio 1.07) or mortality, and did not raise haemorrhage.
Protecting the blood-brain barrier in rats
In rats with transient arterial occlusion, NA-1 preserved the blood-brain barrier, lowered MMP-9 and neuronal nitric oxide synthase, and PSD-95 was found in brain endothelial cells.
Re-engineering for brain delivery
D-amino-acid versions of NA-1 resisted breakdown but bound their target less, and adding a brain-homing peptide increased vascular retention without improving delivery into brain tissue.
Dosing Data
Not approved. All three phase 3 trials gave a single intravenous dose of 2.6 mg/kg, up to 270 mg.
Educational information, not medical advice. Each dose above is tagged with its source: an approved label, a published human study, animal data, or amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.
What a Buyer Needs to Know
What is sold, how it is mixed, stored and taken, and what is known about its safety, quality and legal status. Each part names its source. Where we have none, it says unknown.
What is sold
Unknown: we hold no regulator's label that says in what form Nerinetide is supplied. It is prepared and given by clinical staff, not bought and mixed at home: the next part says where.
Mixing a vial: a worked example
Nothing to mix at home, and no syringe units to work out: Nerinetide is prepared and given by clinical staff, in hospital or an ambulance, during stroke treatment.
In the carded trials it was given into a vein to patients having clot removal (thrombectomy) for stroke.
Source: PMID 32087818 and PMID 39955119 (studies carded under Research below).
Storage before and after mixing
Unknown: no label on file says how Nerinetide is stored. It is kept and prepared by the hospital or clinic that gives it (see the part above); the home rules for a mixed vial in the mixing guide do not apply to it.
How it is taken
As it was given in human studies: Intravenous (Single dose; Trial: ESCAPE-NA1).
Source: Used in human trials: the route and frequency of each row in Dosing Data below.
What to expect, and when
How long it stays in the body: not established by a measurement cited on this entry.
How long the doses were given: Trial: ESCAPE-NA1: Once, around thrombectomy; Trial: FRONTIER (paramedic-delivered): Within 3 hours of symptom onset.
When effects appear: unknown; no source on this page gives a time to effect for Nerinetide. Results reported in the studies are under Published Research.
Source: Used in human trials, the duration of each row in Dosing Data below.
Side effects, and when to stop or get help
From the Side Effects section: Serious adverse events similar to placebo in all three phase 3 trials. Full list and cautions ↓
When to stop or get help: unknown; no label or trial on file sets rules for stopping Nerinetide. Treat a severe or unexpected reaction as a reason to stop and see a doctor.
Source: the Side Effects section below (“From the trials above”).
Interactions
- alteplase: nerinetide is cleaved by plasmin when given after alteplase, which nullifies its benefit; in rats, giving nerinetide before alteplase preserved its effect
Every peptide's record, with its source: the interaction matrix.
Source: human study, PMID 33827973.
Checking what you bought
Unknown: no published independent test of Nerinetide products is in our lab-results database yet, so how products sold under this name measure up is not known.
To read a certificate of analysis, paste it into the COA decoder. Trust & Verification explains what independent testing can and cannot show.
Legal status
US: In Clinical Trials (Not approved anywhere). Sport: Prohibited (S0 catch-all).
Country by country ↓ · Regulatory tracker
Source: this entry's approval status and the WADA Prohibited List, as in Legal Status below.
Side Effects & Contraindications
Reported Side Effects
From the trials above.
Contraindications & Cautions
No label; it is investigational.
Legal Status
Nerinetide is investigational.
Frequently Asked Questions
?What is nerinetide?
An investigational 20-amino-acid peptide meant to protect brain cells during stroke by interfering with post-synaptic density protein 95.
?Did nerinetide work in stroke trials?
Not on their main measures. ESCAPE-NA1, ESCAPE-NEXT and FRONTIER all missed their primary outcomes, although some analyses suggested benefit in patients not given alteplase.
?Why might alteplase matter?
ESCAPE-NA1 found the treatment effect appeared to be inhibited in patients who received alteplase, and imaging analyses showed less infarct growth with nerinetide only in those who did not.
?Is it safe?
Serious adverse events occurred at similar rates to placebo in all three large trials.
?Why was it given by paramedics in one trial?
FRONTIER tested whether starting nerinetide in the ambulance, a median of 64 minutes after symptoms began, would protect the brain before hospital treatment; it did not improve the primary outcome, and those given nerinetide happened to have more severe strokes at baseline.
?Do pooled analyses show nerinetide works?
Not convincingly. Across 2,462 patients in three trials there was no improvement in functional outcome, and only a borderline mortality signal (risk ratio 0.86, p = 0.05).
References
- [clinical-trial] Hill MD, et al. "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial." Lancet, 2020;395(10227):878-887. PMID: 32087818.
- [clinical-trial] Hill MD, et al. "Efficacy and safety of nerinetide in acute ischaemic stroke in patients undergoing endovascular thrombectomy without previous thrombolysis (ESCAPE-NEXT): a multicentre, double-blind, randomised controlled trial." Lancet, 2025;405(10478):560-570. PMID: 39955119.
- [clinical-trial] Christenson J, et al. "Efficacy and safety of intravenous nerinetide initiated by paramedics in the field for acute cerebral ischaemia within 3 h of symptom onset (FRONTIER): a phase 2, multicentre, randomised, double-blind, placebo-controlled study." Lancet, 2025;405(10478):571-582. PMID: 39955120.
- [pubmed] Rex NB, et al. "Nerinetide Reduces Early Infarct Growth Among Stroke Patients Undergoing EVT Without Intravenous Alteplase." Stroke Vasc Interv Neurol, 2024;4(2):e001034. PMID: 41583582.
- [pubmed] Fladt J, et al. "Infarct Evolution on MR-DWI After Thrombectomy in Acute Stroke Patients Randomized to Nerinetide or Placebo: The REPERFUSE-NA1 Study." Neurology, 2024;102(2):e207976. PMID: 38165335.
- [pubmed] Tymianski M, et al. "Safety and efficacy of nerinetide in patients with acute ischaemic stroke enrolled in the early window: a post-hoc meta-analysis of individual patient data from three randomised trials." Lancet Neurol, 2025;24(3):208-217. PMID: 39956129.
- [clinical-trial] Adams C, et al. "Safety and Efficacy of Nerinetide at Year 1 in Participants Enrolled in ESCAPE-NEXT: A Multicenter, Double-Blind, Randomized Controlled Trial." J Am Heart Assoc, 2026;15(13):e044080. PMID: 42333641.
- [pubmed] Khurram L, et al. "Efficacy and Safety of Nerinetide in Acute Ischemic Stroke Patients: A Systematic Review, Meta-Analysis and Meta Regression." Brain Behav, 2025;15(11):e71049. PMID: 41214902.
- [pubmed] Kumar V, et al. "Therapeutic potential of nerinetide in acute ischemic stroke: a comprehensive systematic review and meta-analysis." Ann Med Surg (Lond), 2026;88(1):718-727. PMID: 41497104.
- [pubmed] Abbas A, et al. "Efficacy and safety of intravenous nerinetide in acute ischemic stroke patients undergoing endovascular thrombectomy without thrombolysis: a meta-analysis of randomized controlled trials." Neuroradiology, 2026;68(2):387-395. PMID: 41400652.
- [pubmed] Fujiwara S, et al. "Sex differences in brain frailty measures and outcomes after endovascular thrombectomy: ESCAPE-NA1 analysis." J Neurol Sci, 2026;488:126070. PMID: 42349084.
- [pubmed] Tadros GS, et al. "MRI measurement of the delayed secondary ischaemic injury following endovascular thrombectomy: results from the REPERFUSE-NA1 study." Eur Stroke J, 2026;11(4). PMID: 41955072.
- [pubmed] Ospel JM, et al. "Health economic impact of Nerinetide in addition to mechanical thrombectomy without concurrent alteplase." Interv Neuroradiol, 2026;32(4):1329-1335. PMID: 37590087.
- [pubmed] Xu Y, et al. "PSD-95 inhibitor Tat-NR2B9c (NA-1) protects the integrity of the blood-brain barrier after transient middle artery occlusion in rats by downregulating matrix metalloprotease-9 and upregulating endothelial nitric oxide synthase." Brain Res Bull, 2024;206:110836. PMID: 38042504.
- [pubmed] Kolberg HG, et al. "Modifying the PSD-95 inhibitor NA-1 for brain delivery through proteolytic stabilization and conjugation to the potentially brain homing peptide BR1." Int J Pharm, 2026;687:126434. PMID: 41308958.
Sources & Citations
Studies were read from their PubMed abstracts; a correction notice to the ESCAPE-NEXT one-year paper was noted. Read October 7, 2026.
Medical Disclaimer: This content is for educational and informational purposes only. It is not medical advice, and nothing here is an instruction to obtain or use any compound. Talk to a licensed clinician about your own situation.